Introduction {#S1}
============

Gastrointestinal malignancies are listed among the major causes of cancer death worldwide, being associated with environmental and genetic risk factors such as older age, chronic inflammation, family history, smoking, dietary patterns, overweight and physical inactivity, as well as gut microbiota ([@B140]; [@B157]). Gastric cancer (GC) and colorectal cancer (CRC) are among the top five most incident and deadly cancers worldwide ([@B19]). As surgical techniques improve, as well as radiotherapy, chemotherapy and neoadjuvant therapies, the 5-year survival rate can reach up to 95% for early GC and 90% for localized CRC ([@B209]; [@B208]). However, most patients have advanced-stage disease at diagnosis and so the best surgical window is missed ([@B209]; [@B19]). They develop recurrent loco-regional disease or distant metastases with consequent decrease in survival. The heterogeneity of cancer at molecular, histological and phenotypic levels plays an important role in therapy resistance and tumor recurrence, being cancer stem cells (CSCs) among the major causative factors of cancer heterogeneity and treatment failure ([@B97]; [@B75]). The CSC model of tumor progression hypothesizes that a small subpopulation of cancer cells that display stem-like properties sustains tumor growth, metastasis, relapse and resistance to chemotherapy ([@B97]). CSCs can undergo symmetric and asymmetric divisions, having the ability to give rise to all the different types of cancer cells within the tumor ([@B155]). The origin of CSCs is still unclear and controversial ([@B41]; [@B22]). Various hypotheses suggest that depending on the tumor type, CSCs might be derived from adult stem cells, adult progenitor cells that underwent mutations, or differentiated cells that gained stem-like properties through dedifferentiation ([@B12]; [@B186]). A large number of studies demonstrate that CSCs share biomarkers with normal stem cells, thus specific markers for their identification have been explored in recent years. It is known that some transcription factors (TFs) can be re-expressed or reactivated in CSCs, playing a crucial role in the reprogramming of these cells. This review aims to provide a better understanding on how TFs associated with gastric and colorectal CSCs phenotype can be used for CSCs identification, characterization and targeted therapy.

The Challenges of Cancer Stem Cell Identification {#S2}
=================================================

The identification of normal stem cells is now an easy process due to their well-recognized set of biomarkers whereas the identification of CSCs is a challenging task resulting from their complex phenotype, that differs from one tumor to another ([@B185]). Additionally, CSCs represent a very small percentage of tumor cells within the total tumor mass making even harder their detection in heterogeneous tumors ([@B121]). The use of different combinations of cell-surface markers has been the main strategy to identify CSCs in several tumor types ([@B152]). The cell-surface markers are chosen according to their expression and relevance in the tumor type allowing the separation of CSCs from non-CSCs ([@B185]). In GC and CRC, the list of cell-surface markers capable of identifying CSCs is growing ([Table 1](#T1){ref-type="table"}). This means that the interest in gastric and colorectal CSCs identification and targeting is rising but also means that the already used markers are not uniformly advantageous for CSCs detection. In particular, inconsistencies remain concerning which cell-surface marker may be the ideal marker to identify gastric and colorectal CSCs from cell lines and primary tumors ([@B215]; [@B260]; [@B107]; [@B198]; [@B233]; [@B21]).

###### 

Cancer stem cell (CSC) biomarkers for gastric and colorectal cancer.

                                      **Gastric Cancer**   **Colorectal Cancer**
  ----------------------------------- -------------------- --------------------------
  CD44                                [@B215]; [@B268]     [@B56]; [@B91]
  CD44 combined with CD24             [@B260]              ---
  CD44 combined with CD54             [@B32]               ---
  CD44 combined with EpCAM            [@B80]               [@B42]
  CD44 combined with CD133            ---                  [@B91]
  CD49f                               [@B67]               [@B83]
  CD71                                [@B177]              ---
  CD90                                [@B105]              ---
  CD133                               [@B68]; [@B268]      [@B176]; [@B194]; [@B91]
  CD133 combined with CD166           ---                  [@B42]
  CD184 (CXCR4)                       [@B66]               ---
  CD200                               ---                  [@B267]
  Lgr5                                [@B71]               ---
  Lgr5 combined with EpCAM            ---                  [@B117]
  Lgr5 combined with EpCAM and CD44   ---                  [@B132]
  ALDH                                [@B277]              [@B90]
  SOX2                                [@B180]              [@B217]

The table contains some of the most reported CSCs markers used for both tumor types.

Gastric Cancer {#S2.SS1}
--------------

Several cell-surface markers have emerged for gastric CSC identification. The transmembrane glycoprotein CD44 was the first described cell-surface marker used in gastric CSC identification. [@B215] and his collaborators analyzed a panel of six GC cell lines and in three of them -- NCI-N87, MKN-45 and MKN-74 -- a small CD44^+^ cell subpopulation displayed CSC features such as self-renewal, asymmetric division, spheroid colony formation, and *in vivo* tumorigenic ability. They also observed that the CD44^+^ subpopulation had a higher resistance to anticancer drugs when compared to CD44^--^ cells ([@B215]). However, in the other three cell lines -- AGS, Kato III and MKN28 -- the CD44 cell-surface marker was not able to mark cells with stem cell properties ([@B215]). Clinically, CD44^+^ cancer cells at the invasive GC front are associated with poor patient survival ([@B175]; [@B122]). Later, [@B260] combined CD44 with CD24, a signal transducer, and successfully detected a CD44^+^CD24^+^ cellular subpopulation with CSCs characteristics, such as the capability to self-renew and to originate differentiated progeny ([@B260]). Additionally, they showed that CD44^+^CD24^+^ cells had higher ability to form tumors when injected into immunodeficient mice, compared to the CD44^--^CD24^--^ cells ([@B260]). The CD54 cell-surface marker, also known as ICAM-1 (intercellular adhesion molecule 1), was combined with CD44 to isolate gastric CSCs from tumor tissues and peripheral blood of patients with GC ([@B32]). The CD44^+^CD54^+^ cells exhibited *in vitro* and *in vivo* self-renewal ability, formed gastric tumorspheres and originated tumors similar to the original human tumor when injected into immunodeficient mice ([@B32]). The epithelial cell adhesion molecule (EpCAM) has also been used in combination with CD44 to mark gastric CSCs. The small EpCAM^+^/CD44^+^ subpopulation isolated from primary human GC tissues was more resistant to anticancer drugs including 5-fluorouracil (5-FU), doxorubicin, vinblastine and paclitaxel, when compared with EpCAM^+^/CD44^--^, EpCAM^--^/CD44^+^ and EpCAM^--^/CD44^--^ cells ([@B18]; [@B80]). It also showed capacity to form sphere-like structures in serum free conditions and greater ability to originate tumors in immunocompromised mice ([@B80]). The tumors formed after inoculation of the EpCAM^+^/CD44^+^ cells recapitulated the heterogeneous morphology and phenotype present in the original gastric tumor ([@B80]). Moreover, [@B67] identified another potential gastric CSC marker, the CD49f, an integrin α6 (ITGA6) that is a subunit of laminin receptors. Their work showed that CD49f^+^ cells from GC originated tumors when subcutaneously injected into immunodeficient mice, while CD49f^--^ cells did not ([@B67]). They also demonstrated that some of the CD49f^+^ sphere-forming cells were more resistant to doxorubicin, 5-FU and doxifluridine than the other GC cells studied ([@B67]). Another cell-surface marker identified as a gastric CSC marker is the CD71 transferrin receptor. In this case, it was demonstrated that the CD71^--^ subpopulation from the MKN-1 GC cell line displayed CSC features, contrary to CD71^+^ cells. The CD71^--^ cells were more resistant to 5-FU than CD71^+^, had higher tumorigenic ability and were mostly present in the invasive front of the tumor ([@B177]). The cell-surface glycoprotein CD90 (Thy-1) appeared as a potential gastric CSC marker since it was capable of identifying a small population with *in vivo* tumorigenic and self-renewal ability ([@B105]). Additionally, 25% of the gastric primary tumors possessed higher expression of erb-b2 receptor tyrosine kinase 2 (HER2), which was correlated with the higher expression of CD90 ([@B105]). CD133 (prominin-1), a pentaspan transmembrane glycoprotein, is described as a gastric CSC marker due to the fact that its expression is positively correlated with tumor aggressiveness in GC patients ([@B68]; [@B129]; [@B233]; [@B85]; [@B175]). Zhao et al. showed that the frequency of CD133^+^ in gastric primary tumors samples was higher than CD133^--^ cells and CD133 was associated with poor prognosis in GC ([@B274]). Also, spheroid cells from GC cell lines and primary GC tissues presented CD133 expression and displayed several features of CSCs ([@B268]). New cell-surface markers have emerged in the study of gastric CSCs and demonstrated to be able to mark a small population in GC with stem-like features, specifically Lgr5 (leucine-rich repeat-containing G-protein coupled receptor 5) and CXCR4 (C-X-C chemokine receptor type 4) also known as CD184 ([@B66]; [@B71]). Also, the intracellular enzyme aldehyde dehydrogenase (ALDH) has been used to identify gastric CSCs ([@B277]; [@B233]). [@B277] were able to divide NCI-N87 and SNU-1 GC cell lines into ALDH^+^ and ALDH^--^ cells. The ALDH^+^ cells presented CSC features such as higher levels of SOX2, NANOG and Nestin, formed more sphere-like structures and had higher resistance to 5-FU and cisplatin ([@B277]). They also showed that ALDH^+^ cells were more sensitive to salinomycin, a drug proposed to target CSCs ([@B277]).

Colorectal Cancer {#S2.SS2}
-----------------

Several specific cell-surface markers were used to identify colorectal CSCs ([@B221]; [@B225]; [@B192]; [@B232]; [@B278]; [@B17]; [@B167]; [@B182]; [@B226]). CD133 was shown to be a robust CSC-surface marker in CRC ([@B176]; [@B194]; [@B3]). Positive expression of CD133 was, for the first time, associated with a significantly worse survival and poorer clinical response to 5-FU-based chemotherapy in CRC patients ([@B178]). CD44 is also a valid marker of colorectal CSCs ([@B56]). In combination with EpCAM it has already been considered a better strategy, when compared to CD133 ([@B42]). Furthermore, CD166 (another transmembrane glycoprotein) could be used to co-purify CSCs ([@B42]). More recently, colonospheres and chemoresistant CRC cells were found to be enriched with CD133 and CD44 ([@B91]). A strategy that combines CD133 with CD44, seems to be more reliable to isolate colorectal CSCs from both cell lines and primary tumors ([@B1]). [@B88] showed that CD133 may have a better prognostic capacity *per se*, but the combination of CD133, CD44, and CD166 markers may stratify better the risk of CRC. Lgr5 positivity identifies human colorectal CSCs and is a prognostic factor for CRC ([@B117]; [@B108]). Lgr5 overexpression has been shown to be important in CRC progression, as a result of its role in potentiating the Wnt signaling pathway ([@B27]). [@B46] have shown that Lgr5^+^ CSCs are crucial for the formation of liver metastases, while in the primary tumor Lgr5^--^ cells proliferate and are capable of originating Lgr5^+^ cells, assuring a rapid tumor growth when treatment ends. Lgr5 combined with CD44 and EpCAM can further improve the identification of CSCs in CRC ([@B132]). [@B230] have shown that spheroid cultures of colon CSCs express CD133, CD166, CD44, CD29, CD24, Lgr5, and nuclear *β*-catenin, all of which described markers of the CSC population. Also, CD200 showed a role as a CSC marker in colon cancer, and CD49f was associated with tumor cell invasion and metastasis in colon cancer working as an important marker for identifying colorectal CSCs ([@B197]; [@B83]; [@B267]). ALDH1 also appears as a specific marker for colonic CSCs and as an independent prognostic factor for patients with CRC ([@B90]; [@B146]; [@B113]; [@B72]; [@B278]; [@B167]). In patients with stage II-III rectal cancer that received radio-chemotherapy, ALDH1 expression was correlated with poor prognosis, cancer relapse and metastasis ([@B90]; [@B51]).

Transcription Factors as Potential CSC Markers {#S3}
==============================================

One of the challenges to target CSCs is to identify specific markers as well as to uncover targetable molecular features associated with their phenotype. It is known that normal stem cells and CSCs share core stemness signaling pathways such as Notch, Hedgehog, WNT/*β*-catenin and JAK/STAT, that have pivotal roles in maintaining stem cell properties and regulating their transcriptional program ([@B31]). SOX2, OCT4, KLF4, and NANOG are some of the key TFs known to promote stemness by upregulating genes involved in self-renewal and pluripotency, while suppressing genes involved in differentiation ([@B255]; [@B218]; [@B24]). Key stem cell TFs like SOX2, OCT4, and NANOG have been proven to be overexpressed in CSCs. For that reason, fluorescence reporter systems driven by portions of promoters where these proteins bind were developed to allow CSCs to be labeled and tracked in various types of cancer. These reporter systems seem to be a powerful tool to identify and study CSCs more efficiently than cell-surface markers ([@B202]). [@B218] developed a flexible lentiviral-based reporter system (SORE6-GFP) that allows direct visualization of CSCs based on SOX2 and OCT4 expression. By using this novel reporter system, our group was able to isolate gastric CSCs from two phenotypically different GC cell lines (AGS and Kato III) ([@B180]). Using the same principle, other authors have been developing similar systems to identify and characterize CSCs in a variety of solid tumors. [@B24] established a method using a lentiviral construct carrying the promoter of NANOG to identify prostate CSCs and more recently, [@B69] introduced a similar approach for the isolation of CSCs in a breast cancer cell line based on the single expression of OCT4. Although the use of cell-surface markers is the most trusted approach to detect these cells, several studies demonstrated that they lack specificity and cannot be used for real time assessment of CSCs behavior, which could give new insights about their properties and possible targets ([@B218]). Growing evidences support that specific TFs overexpressed in normal gastrointestinal stem cells may contribute to the self-renewal characteristics of CSCs in GC and CRC and are related with patient prognosis ([@B78]; [@B276]). This makes them a powerful tool in CSCs identification and study.

SOX2 (SRY-Box Transcription Factor 2) {#S3.SS1}
-------------------------------------

SOX2 is a master regulator that belongs to the family of high-mobility group TFs. It plays many roles throughout development and cell differentiation in normal tissues, namely in mammalian embryogenesis, morphogenesis and homeostasis of the foregut-derived epithelia of the esophagus, lung and trachea ([@B7]; [@B201]). SOX2 role in stemness was strengthen with Takahashi and Yamanaka's findings when reprogramming mouse embryonic fibroblasts into induced pluripotent stem (iPS) cells, by introducing SOX2 along with OCT3/4, c-Myc and KLF4 ([@B214]). In cancer, SOX2 has increasingly been associated with a CSC phenotype in several tumors ([@B243]; [@B217]). In GC, SOX2 role is still controversial: some authors associate its high expression with a more aggressive phenotype, poor prognosis and worse response to therapy whereas others have shown the opposite ([@B94]; [@B25]; [@B28]; [@B268]; [@B243]; [@B10]; [@B180]). Our group identified subpopulations of gastric CSCs in two human cell lines based on the expression of SOX2 and showed that SORE6^+^ cells presented CSCs properties, including higher proliferation and ability to form gastrospheres, enhanced *in vivo* tumorigenesis and increased resistance to 5-FU ([@B180]). Additionally, [@B94] observed that inhibition of SOX2 resulted in reduced cell proliferation and migration, increased apoptosis, changes in cell cycle and reduced tumorigenic potential of cells *in vivo*. Similar results were observed *in vivo*, where suppression of SOX2 resulted in reduced tumor growth and decreased tumorigenicity ([@B220]; [@B94]). In CRC, SOX2 overexpression has been associated with tumor progression and disease recurrence and SOX2 *de novo* expression was associated with poorly differentiated and more invasive tumors and poor patient overall survival ([@B149]; [@B148]). [@B217] have shown that SOX2^+^ cells developed chemoresistance to oxaliplatin and 5-FU, exhibiting typical asymmetric cell division and higher CSC markers expression. They concluded that colon cancer cells expressing SOX2 behave like CSCs and are therefore associated with poor prognosis ([@B148]; [@B217]). Taken together, these findings indicate that SOX2 has a critical role in several aspects of CSCs biology.

OCT4 (POU Class 5 Homeobox 1) {#S3.SS2}
-----------------------------

OCT4, a homeodomain TF of the Pit-Oct-Unc family, is expressed in embryonic stem cells, where it maintains stem cell-like properties, and in adult stem cells, being involved in their proliferation and differentiation ([@B142]; [@B82]). Abnormal expression of OCT4 has been observed in different tumor types, including GC and CRC ([@B40]; [@B10]). Studies report that its expression is positively correlated with more aggressive and metastatic tumors, as well as with poorer overall prognosis ([@B268]; [@B10]). Chen and collaborators demonstrated that overexpression of OCT4 in GC cells led differentiated cancer cells to become undifferentiated and acquiring self-renewal capacity ([@B34]) and another study reported that downregulation of OCT4 induced differentiation in GC cells ([@B213]). Additionally, [@B268] demonstrated a p-ERK mediated positive feedback loop between the cell surface marker CD44 and OCT4, responsible for sustaining gastric CSCs properties. OCT4 has also been reported in colon CSCs and its knockdown inhibits cell migration and invasion, suggesting it may act as a novel prognostic marker in CRC ([@B164], [@B163]; [@B40]; [@B5]).

KLF4 (Kruppel Like Factor 4) {#S3.SS3}
----------------------------

KLF4, also known as the gut-enriched Kruppel like factor (GKLF), is strongly expressed in post-mitotic and terminally differentiated epithelial tissues, along with those of the gastrointestinal tract ([@B36]; [@B39]). It is suggested that it may have an anticancer role in GC, being downregulated due to hypermethylation and loss of heterozygosity in gastric CSCs ([@B36]). Several studies have shown that KLF4 low expression is negatively associated with patient overall survival and may be a useful prognostic marker in GC patients ([@B133]; [@B266]; [@B89]; [@B84]; [@B275]). Regarding CRC, KLF4 role is still not clear. Some studies reveal KLF4 is overexpressed in colon CSCs and its knockdown affects the stemness phenotype and decreases the cells malignant profile, while others demonstrate that loss of expression is associated with stem-like features namely formation of colonospheres, cell growth arrest, uncontrolled cell proliferation, pluripotency and self-renewal ([@B205]; [@B238]; [@B131]; [@B78]).

NANOG (Nanog Homeobox) {#S3.SS4}
----------------------

NANOG was first discovered in embryonic stem cells (ESCs) and is a key TF involved in self-renewal and multipotency ([@B29]). It is typically silenced in normal somatic cells, though abnormal expression has been reported in malignant tumors, such as GC and CRC ([@B138]; [@B78]). Previous studies demonstrate that NANOG is highly expressed in GC and significantly associated with tumor size and grade, along with decreased overall survival ([@B100]; [@B10]). Although studies indicate NANOG is associated with a CSC phenotype, it remains unclear its role in CSC maintenance in GC ([@B100]). With respect to CRC, NANOG overexpression has been associated with colony formation and stem cell properties, as well as worse prognosis ([@B95]; [@B263]; [@B78]).

c-Myc (MYC Proto-Oncogene, bHLH Transcription Factor) {#S3.SS5}
-----------------------------------------------------

c-Myc is an essential TF that regulates genes that take part in biological processes such as self-renewal, differentiation, growth and metabolism ([@B43]; [@B20]). Although it is one of the most commonly activated oncogenes involved in the pathogenesis of cancer, its overexpression alone is unable to induce the transformation of normal cells into tumor cells ([@B247]). The role of c-Myc in GC is less studied than in other tumor types. It has been suggested as a CSC marker in some tumors such as small-cell lung cancer, prostate cancer, neuroblastoma, glioblastoma and hematopoietic malignancies, but the expression and relevance in GC has not yet been clarified ([@B247]). Some authors associate c-Myc deregulation with poor prognostic features ([@B81]; [@B47]; [@B236]). Upregulation of c-Myc is common in 70% of CRC cases and it has been shown to have a crucial role in maintaining chemoresistance and self-renewal, being overexpressed in colon CSCs ([@B169]; [@B262]). Despite some controversial results, it has been shown that high expression of c-Myc is an independent poor prognostic factor in CRC ([@B130]; [@B235]).

SOX9 (SRY-Box Transcription Factor 9) {#S3.SS6}
-------------------------------------

SOX9 regulates developmental processes such as male sex determination, chondrogenesis, neurogenesis, and neural crest development ([@B110]). Also, it plays a vital role in cell fate decisions and stem cell maintenance during embryonic development and adulthood in several organs, including the gastrointestinal tract ([@B11]; [@B93]). Its role in GC is still conflicting, while some studies defend an association between lower survival and SOX9 high expression, others demonstrate poor prognosis with a decreased level of SOX9 expression ([@B212]; [@B200]; [@B161]). Also, both oncogenic and tumor suppressor activity of SOX9 have been implicated in CRC ([@B44]; [@B144]; [@B156]; [@B188]). Previous studies suggest that this TF can influence tumor proliferation and progression, mainly through the regulation of the CSC pool, and could correlate with poor prognosis ([@B144]; [@B59]; [@B103]).

GLI1 (GLI Family Zinc Finger 1) {#S3.SS7}
-------------------------------

GLI1 is part of the Sonic Hedgehog (SHH) pathway and seems to be essential for the maintenance of cancer cells with stem like properties in both GC and CRC ([@B268]; [@B248]). In GC, its expression is significantly higher in metastatic cancer tissues and is positively correlated with a more aggressive tumor phenotype ([@B268]). Furthermore, it has been observed that GLI1 overexpression promotes a CSC phenotype enhancing cell proliferation, migration and therapy resistance ([@B55]; [@B250]). GLI1 also plays an important role in CSC characteristics related with aggressiveness and metastatic spread of CRC cells leading to decreased survival. Furthermore, GLI1 knockdown downregulates CD133/SOX9 expression and clonogenic ability of CRC cells, indicating this TF could be a potential marker for CSCs in CRC ([@B248]).

STAT3 (Signal Transducer and Activator of Transcription 3) {#S3.SS8}
----------------------------------------------------------

STAT3 plays an important role in the regulation of various physiological functions, such as inflammation, proliferation and invasion, being highly expressed in gastric and colorectal CSCs ([@B258]; [@B136]; [@B79]; [@B208]). In gastric CSCs, high expression of STAT3 has been reported to be involved in stemness properties and invasive ability ([@B79]; [@B109]; [@B208]). Regarding its prognostic value several studies report STAT3 activation as a marker of unfavorable outcome ([@B118]; [@B50], [@B49]; [@B104]). In CRC, STAT3 is one of the major oncogenic proteins associated with proliferation, angiogenesis, invasion and chemo-radiotherapy resistance ([@B137], [@B136]; [@B167]). Also, its inhibition prevents tumor initiation, being an attractive therapeutic target for CRC ([@B136]).

SALL4 (Spalt Like Transcription Factor 4) {#S3.SS9}
-----------------------------------------

As a TF, SALL4 plays essential roles in maintaining pluripotency and self-renewal of ESCs, being downregulated or silenced in differentiated cells ([@B264], [@B271]; [@B246]). SALL4 acts as an oncogene and it is associated with cancer initiation, development, and progression ([@B151]). [@B265] showed that the overexpression of SALL4 is associated with gastric CSC features and could be involved in the generation and maintenance of these cells. Later, [@B259] suggested a novel mechanism for SALL4 role in GC, showing that this TF binds to the promoter region of CD44 and activates it expression, enhancing cell proliferation, migration and invasion. Increasing evidence indicates that upregulation of SALL4 is associated with lymph node metastasis and poorer overall prognosis ([@B265], [@B272]). In CRC, SALL4 overexpression is detected in 87% of tumor tissues and it is correlated with tumor cell metastasis to lymph nodes being associated with poor prognosis and showing its essential role in maintaining the properties of CSCs ([@B64]; [@B271]).

β-Catenin (Catenin Beta 1) {#S3.SS10}
--------------------------

The Wnt/*β*-catenin pathway is implicated in the regulation of the epithelial stem cell self-renewal ([@B13]). Alone, *β*-catenin signaling has been shown as necessary for the maintenance of CSC features ([@B92]; [@B116]; [@B106]). The dysregulation of the Wnt/*β*-catenin signaling pathway has been implicated in colon carcinogenesis and plays a critical role in regulating the growth and maintenance of colonospheres ([@B123]; [@B116]). The activation of this pathway can lead to the conversion of intestinal stem cells into CSCs, where expression levels of *β*-catenin are higher ([@B116]). Some studies revealed that high levels of nuclear β-catenin, in CRC patients, were associated with a poor prognosis and could be used as a biomarker for late phase CRC ([@B33]). Gastric CSCs self-renewal and proliferation ability, both *in vitro* and *in vivo*, are also improved by the Wnt/*β*-catenin signaling ([@B154]; [@B35]).

CSCs and Tumor Microenvironment {#S4}
===============================

The close interaction between CSCs and their niche is fundamental for maintaining the stemness of CSCs and tumor progression. The CSC niche, a specific tumor microenvironment, which consists of stroma, micro-vessels, hypoxic regions, cancer-associated fibroblasts (CAFs), cancer-associated mesenchymal stem cells (MSCs), tumor-associated macrophages (TAMs) and extracellular matrix, secretes soluble factors (e.g., cytokines and growth factors) that are necessary for cancer cell survival ([@B190]; [@B128]; [@B247]). Growth factors and cytokines regulate Wnt, Notch, JAK-STAT3 and other signaling pathways thereby stimulating growth, epithelial-to-mesenchymal transition (EMT), invasion, angiogenesis, metastasis and inhibiting apoptosis ([@B247]). These pathways are required for the self-renewal and maintenance of CSCs. For instance, growth factors like hepatocyte growth factor (HGF), secreted by the stromal myofibroblasts, activate the Wnt-signaling in a subset of colon cancer cells that maintain the CSC phenotype ([@B229]). Another example is hypoxia, which also maintains a stem-like phenotype in CRC and GC through the increased expression of hypoxia-inducible factors (HIFs), the transcription factors HIF-1α and HIF-2α, that maintain the Wnt/*β*-catenin signaling pathway and activate stemness-related TFs such as OCT4 ([@B70]; [@B139]; [@B158]; [@B253]; [@B224]). On the other hand, cancer cells also secrete growth factors and proteases to promote changes in their microenvironment ([@B99]). One significant example of this crosstalk between cancer cells and the microenvironment is the secretion of cytokines like interleukin-6 (IL-6) by the cancer-associated mesenchymal stem cells that enhance the progression of CRC through the IL-6/JAK2/STAT3 signaling ([@B270]). The same is observed in GC through the secretion of interleukin-8 ([@B134]). On the other hand, cancer cells mediate the production of inflammatory cytokines with pro-tumorigenic roles or the inhibition of cytokines involved in immune surveillance, altering the composition of the immune cells in the tumor microenvironment ([@B190]; [@B240]). Specifically, [@B193] suggested that CSCs could alter the cytokines in the tumor microenvironment by demonstrating that the balance between suppressive regulatory T cells (Treg) and T helper cells producing IL17 (Th17) could be affected. [@B30] disclosed further that STAT3 is fundamental for the inhibition of Treg cells development and Th17 differentiation. In fact, the STAT3 transcription factor, in collaboration with NFκB, regulates the expression of these genes encoding critical cancer-promoting inflammatory mediators, establishing a crosstalk between cancer and immune cells of the microenvironment and perpetuating the effects of STAT3 activation in cancer cells ([@B257]; [@B73]; [@B249]). However, despite the growing evidences on the interaction of gastric and colorectal CSCs with the tumor microenvironment, the specific molecules involved and their signaling pathways still need further investigation in order to design safe therapies.

Therapeutic Approaches to Target CSCs {#S5}
=====================================

The therapeutic approach in GC and CRC is determined by the stage of the disease at the time of diagnosis. Patients are treated with surgery, chemotherapy and/or radiation. In GC, surgery remains the main treatment for stage I. It can also be performed at stages II and III but chemotherapy (perioperative, neoadjuvant or adjuvant) is necessary to improve overall survival of the patients. For stage IV, chemotherapy with doublet or triplet platinum/fluoro-pyrimidine combinations or capecitabine is the main treatment ([@B173]; [@B207]). Resective surgery is the main curative treatment used in non-metastasized CRC, although neo-adjuvant treatments are also administered in rectal carcinoma ([@B125]). After surgery, 5-FU-based chemotherapy is used to reduce the risk of tumor recurrence and improve overall survival of patients ([@B53]). Currently, the decision of giving adjuvant treatment to early-stage CRC patients is recommended to high risk patients with one or more risk factors ([@B115]). Patients with very high risk -- microsatellite stable (MSS) and T4 may be considered for the addition of oxaliplatin ([@B126]). However, in some cases of GC and CRC, after a believed efficacious treatment, the cancer reappears locally or in distant metastasis. This results from the presence of CSCs that were able to resist the therapy applied, revealing that the existence of CSCs is one of the biggest difficulties in cancer treatment ([@B48]). Thus, direct targeting of CSCs seems to be the key for tumor complete elimination. The therapy against CSCs using specific molecules should eradicate these cells while the conventional therapy eliminates the non-CSCs present in the tumor bulk. Nevertheless, this type of treatment should be administrated in combination due to the possibility of cell plasticity that facilitates the appearance of *de novo* CSCs from non-CSCs. Moreover, targeting specific TFs or signaling pathways responsible for maintaining the CSC phenotype could become novel therapies against GC and CRC. For that reason, several clinical trials are being undertaken to explore the efficacy of diverse compounds, that are capable of modulating or inactivating proteins that gastric and colorectal CSCs use to grow and survive, allowing their elimination. Additionally, it is worth to mention that several studies have been conducted to evaluate the efficacy of small molecules in targeting CSCs *in vitro* and *in vivo*, compounds capable of eliminating or reducing the CSC population that could also be part of the path in cancer therapy targeting CSCs ([@B76]; [@B2]; [@B204]; [@B166]; [@B183]; [@B180]). [Table 2](#T2){ref-type="table"} lists the drugs that have been or are being investigated in clinical trials, alone or in combination with other compounds, to treat GC and CRC.

###### 

Complete and ongoing clinical trials of therapeutic agents targeting gastric and/or colorectal CSCs, correlated signaling pathways and the transcription factor STAT3.

  **Drug/Antibody**                                                                                **Targets**                                           **Disease/Condition**                                                                               **NCT Identifier**   **Phase**   **Routes of administration**   **Recruitment status**          **Last update**   **Sponsor**
  ------------------------------------------------------------------------------------------------ ----------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------- ----------- ------------------------------ ------------------------------- ----------------- ------------------------------------------------------------------------
  **Immunotherapy**                                                                                                                                                                                                                                                                                                                                                            
  **RO5429083**                                                                                    CD44                                                  Metastatic and/or locally advanced malignant solid tumors                                           NCT01358903          I           Intravenous (IV)               Completed, no results posted    November 2016     Hoffmann-La Roche
  **Adecatumumab** alone or in combination with FOLFOX                                             EpCAM                                                 R0 resection of colorectal liver metastases                                                         NCT00866944          II          Intravenous (IV)               Completed, no results posted    November 2011     Amgen Research (Munich) GmbH
  **MCLA-158**                                                                                     EGFR and Lgr5                                         Advanced/metastatic solid tumors, including CRC                                                     NCT03526835          I           Intravenous (IV)               Recruiting                      August 2018       Merus N.V.
  **EpCAM CAR-T**                                                                                  EpCAM                                                 Relapsed or refractory EpCAM positive cancer                                                        NCT03013712          I/II        Intravenous (IV)               Recruiting                      January 2017      First Affiliated Hospital of Chengdu Medical College
  **EpCAM CAR-T**                                                                                  EpCAM                                                 Advanced GC with peritoneal metastasis                                                              NCT03563326          I           Intravenous (IV)               Recruiting                      September 2018    Jian-Kun Hu
  **EpCAM CAR-T**                                                                                  EpCAM                                                 GC                                                                                                  NCT02725125          ---         Intravenous (IV)               Unknown                         March 2017        Sinobioway Cell Therapy Co., Ltd.
  **CART-133**                                                                                     CD133                                                 Chemotherapy refractory advanced malignancies, including CRC                                        NCT02541370          I/II        Intravenous (IV)               Completed, no results posted    December 2019     Chinese PLA General Hospital
  **Transcription Factor inhibitors**                                                                                                                                                                                                                                                                                                                                          
  **BBI608** or BNC105 in combination with nivolumab                                               STAT3                                                 Metastatic CRC                                                                                      NCT03647839          II          Oral and Intravenous (IV)      Recruiting                      February 2019     Australasian Gastro-Intestinal Trials Group
  **Danvatirsen (AZD9150)** in combination with Durvalumab (MEDI4736)                              STAT3                                                 Advanced and refractory pancreatic, non-small cell lung cancer, and mismatch repair deficient CRC   NCT02983578          II          Intravenous (IV)               Recruiting                      March 2020        M.D. Anderson Cancer Center
  **Napabucasin (GB201)** in combination with FOLFIRI                                              STAT3                                                 Metastatic CRC                                                                                      NCT03522649          III         Oral and Intravenous (IV)      Recruiting                      June 2019         1Globe Health Institute LLC
  **TTI-101**                                                                                      STAT3                                                 Advanced cancers, including gastric adenocarcinoma and CRC                                          NCT03195699          I           Oral                           Recruiting                      February 2020     Tvardi Therapeutics, Incorporated
  **Artesunate**, prior to surgery                                                                 *β*-catenin                                           Stage II/III CRC                                                                                    NCT02633098          II          Oral                           Recruiting                      April 2019        St George's, University of London
  **DKN-01** in combination with atezolizumab                                                      DKK1                                                  GC                                                                                                  NCT04166721          I/II        Intravenous (IV)               Recruiting                      February 2020     Royal Marsden NHS Foundation Trust
  **ETC-1922159** in combination with pembrolizumab                                                PORCN                                                 Advanced solid tumors                                                                               NCT02521844          I           Oral and Intravenous (IV)      Active, not recruiting          October 2019      EDDC (Experimental Drug Development Centre), A\*STAR Research Entities
  **Foxy-5**                                                                                       Wnt-5A                                                CRC                                                                                                 NCT02020291          I           Intravenous (IV)               Completed, no results posted    February 2016     WntResearch AB
  **Foxy-5**                                                                                       Wnt-5A                                                Metastatic breast, colon or prostate cancer                                                         NCT02655952          I           Intravenous (IV)               Completed, no results posted    December 2018     WntResearch AB
  **Foxy-5** as neo-adjuvant therapy                                                               Wnt-5A                                                Colon cancer                                                                                        NCT03883802          II          Intravenous (IV)               Recruiting                      April 2019        WntResearch AB
  **Genistein** in combination with FOLFOX or FOLFOX-Avastin                                       tyrosine kinase and topoisomerase-II                  Metastatic CRC                                                                                      NCT01985763          I/II        Oral and Intravenous (IV)      Completed, has results          May 2019          Sofya Pintova
  **LGK974**                                                                                       PORCN                                                 Malignancies dependent on Wnt ligands, including BRAF mutant CRC                                    NCT01351103          I           Oral                           Recruiting                      February 2020     Novartis Pharmaceuticals
  **LGK974** in combination with LGX818 and cetuximab                                              PORCN                                                 BRAF-mutant metastatic CRC and Wnt pathway mutations metastatic CRC                                 NCT02278133          I/II        Oral                           Completed, no results posted    October 2017      Array BioPharma
  **MCLA-158**                                                                                     EGFR and LGR5                                         Advanced/metastatic solid tumors, including CRC                                                     NCT03526835          I           Intravenous (IV)               Recruiting                      August 2018       Merus N.V.
  **Mesalazine**                                                                                   induces the expression of μ-protocadherin             CRC                                                                                                 NCT02077777          II          Oral                           Completed, no results posted    December 2016     SOFAR S.p.A.
  **OMP-18R5 (Vantictumab)**                                                                       Wnt receptor                                          Solid tumors                                                                                        NCT01608867          I           Intravenous (IV)               Completed, no results posted    September 2016    OncoMed Pharmaceuticals, Inc.
  **OMP-54F28 (Ipafricept)**                                                                       Wnt receptor                                          Solid tumors                                                                                        NCT01608867          I           Intravenous (IV)               Completed, no results posted    July 2017         OncoMed Pharmaceuticals, Inc.
  **Hedgehog (Hh) pathway inhibitors**                                                                                                                                                                                                                                                                                                                                         
  **BMS-833923 (XL139)**                                                                           Smoothened                                            Advanced or metastatic solid tumors                                                                 NCT01413906          I           Oral                           Completed, no results posted    June 2013         Bristol-Myers Squibb
  **BMS-833923** in combination with cisplatin and capecitabine                                    Smoothened                                            Metastatic gastric, gastroesophageal, or esophageal adenocarcinomas                                 NCT00909402          I           Oral and Intravenous (IV)      Completed, no results posted    June 2013         Bristol-Myers Squibb
  **LDE255 (Sonidegib)** in combination with BKM120 (Buparlisib)                                   Smoothened (and PI3K)                                 Advanced solid tumors                                                                               NCT01576666          I           Oral                           Completed, no results posted    February 2016     Novartis Pharmaceuticals
  **LEQ-506**                                                                                      Smoothened                                            Advanced solid tumors                                                                               NCT01106508          I           Oral                           Completed, no results posted    February 2020     Novartis Pharmaceuticals
  **Vismodegib** in combination with standard chemotherapy                                         Smoothened                                            Advanced GC or gastroesophageal junction cancer                                                     NCT00982592          II          Oral and Intravenous (IV)      Completed, has results          January 2016      National Cancer Institute (NCI)
  **Vismodegib (GDC-0449)** with concurrent chemotherapy and bevacizumab as first-line therapy     Smoothened                                            Metastatic CRC                                                                                      NCT00636610          II          Oral                           Completed, has results          June 2017         Genentech, Inc.
  **NOTCH pathway inhibitors**                                                                                                                                                                                                                                                                                                                                                 
  **BMS-906024**                                                                                   Pan-Notch                                             Advanced or metastatic solid tumors                                                                 NCT01292655          I           Intravenous (IV)               Completed, no results posted    January 2020      Bristol-Myers Squibb
  **CB-103**                                                                                       Pan-Notch                                             Advanced or metastatic solid tumors, including CRC                                                  NCT03422679          I/II        Oral                           Recruiting                      May 2019          Cellestia Biotech AG
  **LY3039478 (Crenigacestat)**                                                                    Pan-Notch                                             Advanced solid tumors                                                                               NCT02836600          I           Oral                           Active, not recruiting          December 2019     Eli Lilly and Company
  **LY3039478 (Crenigacestat)** in combination with other anticancer agents                        Pan-Notch                                             Advanced or metastatic solid tumors                                                                 NCT02784795          I           Oral and Intravenous (IV)      Completed, no results posted    March 2020        Eli Lilly and Company
  **LY900009**                                                                                     γ-Secretase                                           Advanced cancer                                                                                     NCT01158404          I           Oral                           Completed, has results          August 2019       Eli Lilly and Company
  **MEDI0639**                                                                                     DLL4                                                  Advanced solid tumors                                                                               NCT01577745          I           Intravenous (IV)               Completed, has results          May 2017          MedImmune LLC
  **REGN421 (SAR153192; Enoticumab)**                                                              DLL4                                                  Advanced solid malignancies                                                                         NCT00871559          I           Intravenous (IV)               Completed, no results posted    March 2014        Regeneron Pharmaceuticals
  **RO4929097**                                                                                    γ-Secretase                                           Recurrent and metastatic CRC                                                                        NCT01116687          II          Oral                           Completed, has results          May 2014          National Cancer Institute (NCI)
  **RO4929097** in combination with capecitabine                                                   γ-Secretase                                           Refractory solid tumors                                                                             NCT01158274          I           Oral                           Completed, no results posted    November 2014     National Cancer Institute (NCI)
  **RO4929097** in combination with cediranib maleate                                              γ-Secretase                                           Advanced solid tumors including CRC                                                                 NCT01131234          I           Oral                           Completed, no results posted    December 2014     National Cancer Institute (NCI)
  **PI3K/AKT/mTOR pathway inhibitors**                                                                                                                                                                                                                                                                                                                                         
  **Acetylsalicylic acid (aspirin)**                                                               ---                                                   CRC stage I-III with mutations in the PI3K signaling pathway                                        NCT02647099          III         Oral                           Recruiting                      August 2019       Anna Martling
  **Acetylsalicylic acid (aspirin)**                                                               ---                                                   Resected colon cancer with PI3K mutation stage II or III high risk                                  NCT02945033          III         Oral                           Recruiting                      October 2019      University Hospital, Rouen
  **Acetylsalicylic acid (aspirin)**                                                               ---                                                   Dukes C and high-risk dukes B CRCs                                                                  NCT00565708          III         Oral                           Recruiting                      September 2019    National Cancer Centre, Singapore
  **Acetylsalicylic acid (aspirin) and metformin**                                                 ---                                                   Stage I--III CRC patients                                                                           NCT03047837          II          Oral                           Recruiting                      February 2019     Ente Ospedaliero Ospedali Galliera
  **AZD2014 (Vistusertib)**                                                                        mTORC1 and mTORC2                                     RICTOR amplified GC                                                                                 NCT03061708          II          Oral                           Terminated (lack of efficacy)   May 2019          Samsung Medical Center
  **AZD2014 (Vistusertib)**                                                                        mTORC1 and mTORC2                                     TSC1/2 mutated or TSC1/2 null GC                                                                    NCT03082833          II          Oral                           Terminated (lack of efficacy)   May 2019          Samsung Medical Center
  **AZD5363** in combination with paclitaxel                                                       AKT                                                   Advanced gastric adenocarcinoma                                                                     NCT02451956          II          Oral and Intravenous (IV)      Completed, no results posted    December 2019     Samsung Medical Center
  **AZD8186** in combination with paclitaxel                                                       PI3K β/δ                                              Advanced GC                                                                                         NCT04001569          I/II        Oral and Intravenous (IV)      Recruiting                      June 2019         Seoul National University Bundang Hospital
  **BKM120 (Buparlisib)** in combination with LDE255 (Sonidegib)                                   PI3K and Smoothened                                   Advanced solid tumors                                                                               NCT01576666          I           Oral                           Completed, no results posted    February 2016     Novartis Pharmaceuticals
  **BYL719 (Alpelisib)** in combination with AUY922                                                PI3K                                                  Advanced or metastatic GC                                                                           NCT01613950          I           Oral and Intravenous (IV)      Completed, no results posted    February 2020     Novartis Pharmaceuticals
  **BYL719 (Alpelisib)** in combination with LGX818 (Encorafenib) and Cetuximab                    BRAF, EGFR and PI3K                                   in BRAF Mutant Metastatic CRC                                                                       NCT01719380          I/II        Oral and Intravenous (IV)      Completed, no results posted    April 2019        Array BioPharma
  **Cabozantinib**                                                                                 Multikinases                                          Refractory metastatic CRC                                                                           NCT03542877          II          Oral                           Active, not recruiting          April 2019        Academic Thoracic Oncology Medical Investigators Consortium
  **CB-839 (Telaglenastat)** in combination with capecitabine                                      Glutaminase                                           Solid tumors and fluoropyrimidine resistant PIK3CA mutant CRC                                       NCT02861300          I/II        Oral                           Recruiting                      March 2020        Case Comprehensive Cancer Center
  **Copanlisib** in combination with anti-PD-1 antibody Nivolumab                                  PI3K                                                  Relapsed/refractory solid tumors, mismatch-repair proficient (MSS) CRC                              NCT03711058          I/II        Intravenous (IV)               Recruiting                      July 2019         Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  **DS-7423**                                                                                      PI3K and mTOR                                         Advanced solid malignant tumors                                                                     NCT01364844          I           Oral                           Completed, no results posted    February 2014     Daiichi Sankyo, Inc.
  **Ipatasertib (GDC-0068)** in combination with oxaliplatin, 5-FU and leucovorin                  AKT                                                   Advanced or metastatic GC or gastroesophageal junction cancer                                       NCT01896531          II          Oral and Intravenous (IV)      Active, not recruiting          February 2020     Genentech, Inc.
  **MK-2206**                                                                                      AKT                                                   Advanced GC or gastroesophageal junction cancer                                                     NCT01260701          II          Oral                           Completed, has results          January 2016      National Cancer Institute (NCI)
  **MK-2206**                                                                                      AKT                                                   CRC that is metastatic or locally advanced and cannot be removed by surgery                         NCT01802320          II          Oral                           Completed, has results          September 2019    National Cancer Institute (NCI)
  **MK-2206** in combination with AZD6244 (Selumetinib)                                            AKT and MEK                                           Advanced CRC                                                                                        NCT01333475          II          Oral                           Completed, has results          September 2015    National Cancer Institute (NCI)
  **Neratinib** in combination with Trastuzumab or with Cetuximab                                  HER2 and EGFR                                         KRAS/NRAS/BRAF/PIK3CA wild-type metastatic CRC by HER2 status                                       NCT03457896          II          Oral                           Recruiting                      November 2019     NSABP Foundation Inc
  Pembrolizumab (MK-3475) combined with **INCB050465** or with Itacitinib (INCB039110)             JAK1 and PI3K-delta                                   Advanced solid tumors, including CRC                                                                NCT02646748          I           Oral                           Active, not recruiting          December 2019     Incyte Corporation
  **PX-866 (Sonolisib)** in combination with Cetuximab                                             PIP3                                                  Incurable metastatic CRC                                                                            NCT01252628          I/II        Oral                           Completed                       May 2018          Cascadian Therapeutics Inc.
  **RAD001 (Everolimus)**                                                                          TOR serine-threonine kinases                          Previously treated unresectable or metastatic esophageal cancer or GC                               NCT00985192          II          Oral                           Completed, has results          February 2020     Translational Oncology Research International
  **RAD001 (Everolimus)**                                                                          TOR serine-threonine kinases                          Advanced GC                                                                                         NCT00519324          II          Oral                           Completed, no results posted    November 2015     Novartis Pharmaceuticals
  **RAD001 (Everolimus)** in combination with AV-951(Tivozanib)                                    TOR serine-threonine kinases and VEGFRs 1, 2, and 3   Gastrointestinal cancer                                                                             NCT01058655          I/II        Oral                           Completed, has results          April 2017        Dana-Farber Cancer Institute
  **RAD001 (Everolimus)** in combination with Capecitabine and Oxaliplatin                         TOR serine-threonine kinases                          Advanced GC                                                                                         NCT01049620          I           Oral and Intravenous (IV)      Completed, no results posted    January 2020      Asan Medical Center
  **RAD001 (Everolimus)** in combination with cisplatin and HDFL (high-dose 5-FU and leucovorin)   TOR serine-threonine kinases                          Advanced GC                                                                                         NCT00632268          II          Oral and Intravenous (IV)      Completed, no results posted    August 2013       National Taiwan University Hospital
  **SAR245409 (Voxtalisib)** in combination with MSC1936369B (pimasertib)                          PI3K, MTOR, MEK1 and 2                                Advanced or metastatic solid tumors (GC not included)                                               NCT01390818          I           Oral                           Completed, has results          March 2017        EMD Serono
  **Serabelisib** in combination with Canagliflozin                                                PI3Kα and SGLT2                                       Advanced solid tumors                                                                               NCT04073680          I/II        Oral                           Not yet recruiting              February 2020     Petra Pharma
  **SF1126**                                                                                       PI3K                                                  Solid tumors                                                                                        NCT00907205          I           Intravenous (IV)               Completed, no results posted    June 2013         Semafore Pharmaceuticals
  **Trametinib** in combination with Trifluridine and Tipiracil Hydrochloride                      MEK                                                   Chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-Wild-Type) metastatic CRC                           NCT03317119          I           Oral                           Recruiting                      January 2020      City of Hope Medical Center

GC corresponds to gastric cancer and CRC to colorectal cancer. FOLFOX corresponds to a chemotherapy regimen with folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin (Eloxatin) and FOLFIRI corresponds to a chemotherapy regimen with folinic acid (leucovorin), fluorouracil (5-FU) and irinotecan (Camptosar).

Immunotherapy {#S5.SS1}
-------------

Cancer immunotherapy has emerged as a potential tool for cancer treatment ([@B62]). Several immunotherapeutic strategies have been developed including cancer vaccines, oncolytic viruses, monoclonal antibodies or recombinant proteins, chimeric antigen receptor T cell (CAR-T) cells and other cellular therapies, lymphocyte-activating cytokines and checkpoint inhibitors ([@B195]). Immunotherapy aims to improve the immune system response against cancer cells through natural mechanisms ([@B195]). Therefore, it can be used to target cancer cells and also CSCs in the tumor microenvironment ([@B8]). Many immunotherapeutic agents targeting CSCs have been tested in clinical trials ([@B160]). Monoclonal antibodies that specifically target CSC surface biomarkers have been used in gastric and colorectal cancer. Ongoing there is a Phase I study of RO5429083, a monoclonal antibody against CD44 in patients with metastatic and/or locally advanced malignant solid tumors (NCT01358903). Also used were EpCAM antibodies, such as edrecolomab, that was tested in patients with resected stage II adenocarcinoma of the colon ([@B174]) and adecatumumab, that is being tested in a Phase II study to evaluate efficacy and safety, alone or with FOLFOX, in metastasized CRC (NCT00866944). A Phase I dose finding study is evaluating the bispecific antibody targeting EGFR and Lgr5 (MCLA-158) in metastatic CRC and other advanced solid tumors (NCT03526835). In addition, CAR-T cell therapies, have been developed to target CSCs in GC and CRC. There are three Phase I or II clinical trials in GC using CAR-T cells targeting EpCAM (NCT03013712, NCT03563326, and NCT02725125), one of them consisting in the intraperitoneal infusion in advanced GC with peritoneal metastasis. NCT03013712 includes patients with colon cancer. Moreover, there is a Phase I/II clinical study of CAR-T cells targeting CD133 in relapsed and/or chemotherapy refractory malignancies including CRC (NCT02541370).

Targeting the Transcription Factor STAT3 {#S5.SS2}
----------------------------------------

From the list of TFs strongly associated with CSC phenotype in GC and CRC, STAT3 became crucial as a molecular target for cancer therapy because napabucasin (BBI608), the first-in-class cancer stemness (CSCs) inhibitor that works by targeting STAT3, effectively blocks cancer relapse and metastasis in xenografted human cancers ([@B135]; [@B269]). Napabucasin is a naturally occurring drug orally administered. It inhibits CSC self-renewal and induces apoptosis in CSCs by targeting CSC signaling pathways (STAT3, NANOG and *β*-catenin) in GC ([@B14]). In CRC, napabucasin has been investigated in several studies. A phase I/II clinical trial investigated napabucasin with other standard therapeutic treatments for advanced gastrointestinal malignancies ([@B15]). Another study -- CanStem303C -- a randomized phase III clinical trial done in adult patients with previously treated metastatic CRC evaluated napabucasin in combination with FOLFIRI ([@B74]). Napabucasin monotherapy has been reported in a published phase III trial. The CO.23 trial evaluated the efficacy of napabucasin monotherapy versus placebo in metastasized CRC, which failed to demonstrate a significant difference in the napabucasin group survival. However, in a pre-specified biomarker analysis, phosphorylated STAT3 (pSTAT3)-positive patients experienced a significant survival benefit from napabucasin over placebo ([@B112]; [@B208]). Another ongoing trial involving STAT3 inhibition is the phase II trial MODULATE (NCT03647839) which specifically aims to study the modulation of the tumor microenvironment using either vascular disrupting agents (BNC105) or STAT3 inhibition (BBI608), in synergy with an immune checkpoint protein (PD1) inhibitor (nivolumab). This trial is recruiting microsatellite stable, refractory CRC cases.

Targeting the Wnt/β-Catenin Signaling Pathway {#S5.SS3}
---------------------------------------------

Wnt/*β*-catenin signaling pathway is a major regulator of normal intestinal development and its over-activation behaves as a hallmark of CRC, being particularly significant in drug resistance and stemness maintenance of colorectal CSCs ([@B216]; [@B12]). The activation of the Wnt/*β*-catenin signaling pathway is associated with poor prognosis ([@B102]). It results mostly from the accumulation of mutations in the APC tumor suppressor gene, oncogenic KRAS-signaling pathway, *β*-catenin and p53. Mutations that do not allow the formation of the APC/Axin/GSK3*β* destruction complex result in the accumulation and nuclear translocation of β-catenin that binds to transcription factors of T cell factor family (TCF4) and activates target genes like c-Myc, cyclinD1 and survivin, some involved in maintaining stemness ([@B170]; [@B130]; [@B278]). It has been shown that loss of APC in CRC triggered the expression of a Rac1 GTPase via the induced expression of c-Myc, necessary to intestinal stem cell proliferation and CRC initiation ([@B170]). On the other hand, p53 may affect the outcome of Wnt signaling in CRC development ([@B231]), having a role in the acquisition of pluripotency during reprogramming ([@B214]; [@B124]). The Wnt signaling pathway is also dysregulated in GC ([@B35]). However, the involvement and mechanisms are not yet as fully understood as in CRC. A number of studies suggest β-catenin and APC as driver genes, revealing somatic mutations in both genes that might have relevance in GC ([@B87]; [@B171]; [@B242]; [@B37]; [@B261]). Genomic analysis of several gastric primary tumors disclosed that Wnt/*β*-catenin, together with NF-κB and proliferation/stem cell pathways, were deregulated in more than 70% of the primary tumors. Patient stratification by combinations of these oncogenic pathways revealed to be a great tool for GC clinical behavior assessment ([@B179]). Many molecules have been used to target the Wnt/*β*-catenin in gastrointestinal CSCs ([@B35]; [@B182]; [@B184]; [@B247]). Genistein, a soy-derived compound, was tested in a Phase I/II research trial, in combination with FOLFOX or FOLFOX-Bevacizumab, where it was demonstrated to be well tolerated by patients and may have improved efficacy in the treatment of metastatic CRC ([@B187]). *In vitro* and *in vivo* studies have shown that Genistein affects mainly Wnt/*β*-catenin and PI3K/AKT pathways ([@B211]; [@B119]; [@B273]; [@B234]).

Targeting the Hedgehog Signaling Pathway {#S5.SS4}
----------------------------------------

The dysregulation of Hedgehog (Hh) signaling pathway has been reported as another main cause of CSCs self-renewal and chemoresistance, being associated with poor clinical outcome in patients with GC or CRC ([@B150]; [@B227]; [@B216]; [@B223]). In this pathway, target gene expression is predominantly regulated by the Smoothened (SMO) protein but GLI inhibitors are also used ([@B196]; [@B52]). In GC cells, SMO regulates nuclear translocation of GLI-1 that in turn promotes transcription of target genes, such as CD44 ([@B254]). [@B254] showed that in AGS, MKN-45, and NCI-N87 GC cell lines, the Hh pathway inhibition using SMO shRNA or small-molecule inhibitors significantly decreased spheroid formation ability and tumor growth. Vismodegib (GDC-0449), the first Hh pathway inhibitor used in cancer research, is currently undergoing Phase II trials in advanced GC and in metastatic CRC ([@B77]; [@B16]). Examination of tumor samples revealed that Vismodegib has not increased progression-free or overall survival as a whole, but only in a limited subset of patients with high CD44 expression ([@B38]; [@B254]). Disappointingly, these treatments with Vismodegib, did not increase progression-free survival in CRC patients ([@B143]; [@B159]). When the SMO inhibitor AY9944 was used in combination with the GLI-1 inhibitor GANT61, there was an increased response to anti-cancer drugs in tumor organoids and a decreased capacity to form colonies in SW480 and HCT116 CRC cells ([@B223]). These results indicate that this strategy might be worthwhile in CRC.

Targeting the Notch Signaling Pathway {#S5.SS5}
-------------------------------------

The Notch signaling pathway is one of the most activated signaling pathways in cancer, namely in GC and CRC, and promotes metastization ([@B57]; [@B86]). It has a key role in the maintenance and differentiation of CSCs ([@B189]; [@B145]; [@B247]). In GC and CRC, the expression of Notch1 or Jagged1 is associated with poor prognosis ([@B252]; [@B114]; [@B101]; [@B120]; [@B165]). In CRC, Notch1 is associated with more aggressive subtypes, recruiting neutrophils to drive metastasis ([@B101]). Due to the fact that the Notch pathway is related to CSC self-renewal and angiogenesis, targeting this pathway became a potential anti-CSC therapeutic approach ([@B228]). Strategies used to inhibit Notch signaling include γ-secretase inhibition (GSI), Notch receptor (e.g., Notch1, Notch2, and Notch3) or ligand (e.g., Jagged1 and Jagged2) antibodies and combination therapy with inhibitors of other pathways. The inhibition of Notch receptors using two GSIs has allowed to disclose the importance of Notch pathway in the growth and survival of GC cells ([@B23]). Furthermore, GSIs lead to the induction of apoptosis and inhibition of tumor-sphere formation of CD44^+^ gastric CSCs ([@B9]). However, it is important to mention that GSIs do not only target Notch-related proteins but also proteases involved in numerous cellular processes, which could originate adverse effects *in vivo* ([@B206]; [@B237]; [@B23]). Nevertheless, various clinical trials have been performed to evaluate the efficacy of targeting the Notch signaling pathway in GC and CRC ([Table 2](#T2){ref-type="table"}). RO4929097, a selective GSI, showed good anti-tumor activity in preclinical and early trials but it was not good enough for metastatic CRC ([@B147]; [@B210]; [@B222]). Combinations of RO4929097 with other drugs in advanced solid tumors, including CRC, were well tolerated and presented some clinical benefit ([@B199]; [@B141]). LY900009 is another GSI tested in advanced cancers, including those of gastrointestinal tract. It is currently in a phase I trial and revealed a safety profile, with the majority of patients experiencing low-grade gastrointestinal adverse effects ([@B181]). Furthermore, it was demonstrated to have an inhibitory effect on Notch signaling pathway, inducing goblet cell differentiation and increased mucin production, similarly to that observed in rats ([@B181]). Moreover, MEDI0639 is a monoclonal antibody that specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and target gene transcription, which may block tumor angiogenesis and eventually tumor cell growth ([@B98]). A phase I study in advanced solid tumors demonstrated that MEDI0639 is well tolerated and preliminary results show evidence of antitumor activity ([@B60]).

Targeting the PI3K/AKT/mTOR Signaling Pathway {#S5.SS6}
---------------------------------------------

The PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway is typically abnormally activated in many carcinomas ([@B162]; [@B111]; [@B172]). It is thought to be crucial in angiogenesis, cell proliferation, metabolism, survival, metastasis and drug resistance ([@B26]; [@B58]; [@B63]; [@B4]; [@B219]). AKT is commonly overexpressed in tumors and plays an important role in the metabolic reprogramming of cancer ([@B251]; [@B96]). Although the PI3K/AKT/mTOR pathway has been extensively studied, there are few studies in CSCs. In GC and CRC, activation of mTOR appears to cause tumor progression and poor patient survival ([@B127]; [@B168]; [@B245]; [@B256]; [@B6]). Thus, its inhibition seems to be fundamental for GC and CRC therapy. A phase II study using RAD001 (everolimus) in previously treated unresectable or metastatic esophageal cancer or GC was performed over the rational that everolimus may stop tumor growth by blocking some of the fundamental enzymes for cell growth and by blocking angiogenesis. Everolimus was well tolerated by the patients however this study displayed a strong weakness by being single-arm and non-comparative. However, mTOR suppression decreased ALDH1 activity, which is a marker of CSCs in CRC ([@B244]). Growth inhibition, using a dual PI3K/mTOR inhibitor, PF-04691502, was observed *in vitro* and in xenografted CRC tumors ([@B61]). Another mTOR inhibitor decreased survival and invasion of colorectal CSCs *in vitro*, and suppressed tumor growth *in vivo* ([@B65]). The allosteric AKT inhibitor (MK-2206) led to a decrease in CSCs proliferation, and reduction of the capacity to form colonospheres *in vitro* and to initiate tumor formation *in vivo*. Mice with xenografted tumors showed a significant decrease in tumor progression. Also, MK-2206 significantly inhibited the growth of patient-derived tumorspheres ([@B153]). A phase II study in advanced gastric or gastroesophageal junction cancer has revealed that MK-2206, as second-line therapy, at a dose of 60 mg was well tolerated by patients and showed some modest evidence of activity, however, the overall survival (5.1 months) was lower than the study efficacy endpoint (6.5 months) ([@B191]). However, there is a Phase II clinical trial with MK-2206, to study patients with previously treated colon or rectal cancer that has spread and cannot be removed by surgery, concluding that in contrast to robust preclinical data, it does not have effect in these tumors ([@B45]). MK-2206 was also used in combination with AZD6244 (Selumetinib), a mitogen-activated protein extracellular signal-regulated kinase (MEK)1/2 inhibitor, in a Phase II trial but the level of target inhibition obtained with the maximum non-toxic dose was not the expected ([@B54]). SAR245409 (Voxtalisib) was tested in a Phase I research trial in combination with another MEK inhibitor, MSC1936369B (Pimasertib), in advanced or metastatic solid tumors ([@B203]). The primary purpose of the study was to determine the maximum tolerated dose of the drug combination. The drug RAD001 (Everolimus) downregulates mTOR. A combination of RAD001, mFOLFOX-6 and Bevacizumab has been shown to be efficacious and safe in metastatic CRC ([@B239]). A multicenter phase II study for patients with refractory, metastatic CRC concluded good tolerability and efficacy of Everolimus combined with Tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) with 50% of the patients having stable disease at 2 months ([@B241]).

Discussion {#S6}
==========

The identification of CSCs remains a challenging task, particularly in solid tumors like GC and CRC. The use of cell surface markers as a primary tool to identify gastric and colorectal CSCs has disclosed some weaknesses and for that reason the uncovering of more reliable biomarkers must become a priority. These biomarkers should include the TFs that are required for the maintenance of gastric and colorectal CSCs phenotype, as well as components of the signaling pathways that have key roles in CSC features. This explains why TFs such as STAT3 and signaling pathways like Wnt/*β*-catenin, Hedgehog, NOTCH and PI3K/AKT/mTOR emerged as powerful targets, whose inactivation or modulation could eliminate gastric and colorectal CSCs. This fact is corroborated by several completed and ongoing clinical trials targeting these potential biomarkers in both tumor types, where some of the molecules have shown promising results. The incapacity to achieve the wanted levels of target inhibition was the major shortcoming of the clinical trials. Yet, the use of higher doses is not possible due to toxicity problems, which led to the development of combinations of drugs targeting different pathways. Furthermore, it is more advisable to measure the outcome of the treatments in terms of CSCs behavior, by assessing capacity to metastasize and re-growth after removing the drug.

Future Perspectives {#S7}
===================

The validation of potential gastric and colorectal CSCs biomarkers and their association with GC and CRC stage is imperative to understand patient prognosis and apply a more suitable therapy. The development of a robust therapy combining CSC targets with conventional chemotherapy could be the solution to overcome resistance to anti-cancer drugs and completely eliminate cancer. Considering these issues, it is crucial that future studies further explore the role of TFs and components of signaling pathways on cancer stemness in order to develop therapies that could eradicate CSCs.
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